Top Two Hot of the Day: Tiffany & Co. (NYSE:TIF), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Tiffany & Co. (NYSE:TIF)

Tiffany & Co. (NYSE:TIF) closed at $115.21 on the last trading session with an decrease of -1.05%, whereas, it previously closed at $116.43. The company has a market capitalization of $14.03 Billion. The company traded shares of 879431 on the trading day while its three month average volume stands at 1.84 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Tiffany & Co. (NYSE:TIF) produced diluted EPS of 4.75. The EPS estimate for next year as estimated by analysts is at 5.46 while EPS for next quarter is estimated at 0.78. Earnings per Share growth for this year is reported at 15.7, while the analysts estimated the EPS growth for next year at 5.46% and Earnings growth for next 5 years stands at 11.63% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 4.9%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Tiffany & Co. (NYSE:TIF) is at 24.28 while the forward p/e is at 21.1. The P/S or Price to Sales ratio of Tiffany & Co. (NYSE:TIF) stands at 3.17 and Price to Book or P/B for the most recent quarter stands at 4.64. The Price to Free Cash Flow ratio or P/FCF is reported at 61.17. The quick ratio and the current ratio of Tiffany & Co. (NYSE:TIF) are reported at 2.1 and 6 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Tiffany & Co. (NYSE:TIF) stands at 8.4, 14.1 and 13 respectively

The trailing twelve month Revenue of Tiffany & Co. (NYSE:TIF) is reported at 4.42 Billion with income of 592.1 Million. The outstanding shares of Tiffany & Co. (NYSE:TIF) are 121.79 Million. The institutional Ownership of the shares of 93.5 stands at 0.80%, this figure is decreased -0.74 in the last six months. The insider ownership for the shares of Tiffany & Co. (NYSE:TIF) is ticked at 0.4%, the figure is plummeted -7.33% in the last six months.

Some other important financial aspects to be discussed here for Tiffany & Co. (NYSE:TIF) is the Mean Target Price estimated by the analysts which stands at 139.83. The 52 week high of Tiffany & Co. (NYSE:TIF) is placed at 141.64 and 52 week low is standing at 90.46.

Performance wise the shares of Tiffany & Co. (NYSE:TIF) rose up 5.12% for the week, it also fell -5.47% for the monthly performance, while for the quarter it went up -15.84%. The shares increase 11.46% for the half year and flew up for the Year-To-Date performance. The shares of Tiffany & Co. (NYSE:TIF) grew 23.9% for the yearly performance.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) closed at $159.98 on the last trading session with an increase of 0.41%, whereas, it previously closed at $159.33. The company has a market capitalization of $3.49 Billion. The company traded shares of 839142 on the trading day while its three month average volume stands at 593.49 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) produced diluted EPS of 6.38. The EPS estimate for next year as estimated by analysts is at 5.55 while EPS for next quarter is estimated at 1.03. Earnings per Share growth for this year is reported at 95.4, while the analysts estimated the EPS growth for next year at 5.55% and Earnings growth for next 5 years stands at 30% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 74.6%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is at 25.08 while the forward p/e is at 28.84. The P/S or Price to Sales ratio of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stands at 15.17 and Price to Book or P/B for the most recent quarter stands at 5.48. The Price to Free Cash Flow ratio or P/FCF is reported at 18.27. The quick ratio and the current ratio of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) are reported at 2.3 and 2.3 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stands at 12.1, 25 and 8.7 respectively

The trailing twelve month Revenue of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is reported at 230 Million with income of 152.3 Million. The outstanding shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) are 21.81 Million. The institutional Ownership of the shares of 0 stands at 0.80%, this figure is decreased -0.46 in the last six months. The insider ownership for the shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is ticked at 2.1%, the figure is plummeted -32.74% in the last six months.

Some other important financial aspects to be discussed here for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is the Mean Target Price estimated by the analysts which stands at 248.17. The 52 week high of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is placed at 278.62 and 52 week low is standing at 126.50.

Performance wise the shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) fell down -7.57% for the week, it also fell -35.26% for the monthly performance, while for the quarter it went up -32.87%. The shares decrease -5.33% for the half year and flew up for the Year-To-Date performance. The shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) grew 8.86% for the yearly performance.